- Home
- VTGN vs LTRN Comparison
VTGN vs LTRN Comparison
Compare VTGN & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | LTRN |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 22.2M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VTGN | LTRN |
|---|---|---|
| Price | $0.69 | $3.73 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $0.90 | N/A |
| AVG Volume (30 Days) | ★ 820.6K | 231.6K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $1.11 |
| 52 Week High | $5.14 | $5.74 |
Technical Indicators
Market Signals| Indicator | VTGN | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 57.11 |
| Support Level | $0.54 | $3.25 |
| Resistance Level | $0.77 | $3.79 |
| Average True Range (ATR) | 0.06 | 0.41 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 79.43 | 50.54 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.